ATE410158T1 - Fulvinsäure und deren verwendung in der behandlung von viralen infektionen - Google Patents

Fulvinsäure und deren verwendung in der behandlung von viralen infektionen

Info

Publication number
ATE410158T1
ATE410158T1 AT06012243T AT06012243T ATE410158T1 AT E410158 T1 ATE410158 T1 AT E410158T1 AT 06012243 T AT06012243 T AT 06012243T AT 06012243 T AT06012243 T AT 06012243T AT E410158 T1 ATE410158 T1 AT E410158T1
Authority
AT
Austria
Prior art keywords
viral infections
fulvic acid
treatment
condition
composition
Prior art date
Application number
AT06012243T
Other languages
English (en)
Inventor
Johannes Dekker
Constance Elizabeth Medlen
Original Assignee
Pfeinsmith Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfeinsmith Ltd filed Critical Pfeinsmith Ltd
Application granted granted Critical
Publication of ATE410158T1 publication Critical patent/ATE410158T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT06012243T 1998-10-08 1999-10-08 Fulvinsäure und deren verwendung in der behandlung von viralen infektionen ATE410158T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA989190 1998-10-08
ZA992848 1999-04-21

Publications (1)

Publication Number Publication Date
ATE410158T1 true ATE410158T1 (de) 2008-10-15

Family

ID=27144980

Family Applications (4)

Application Number Title Priority Date Filing Date
AT99970022T ATE336997T1 (de) 1998-10-08 1999-10-08 Fulvinsäure und dessen verwendung zur behandlung von diversen krankheitszuständen
AT06012245T ATE410160T1 (de) 1998-10-08 1999-10-08 Fulvinsäure und deren verwendung in der behandlung von entzündungen
AT06012244T ATE410159T1 (de) 1998-10-08 1999-10-08 Fulvinsäure und deren verwendung in der behandlung von candida infektionen
AT06012243T ATE410158T1 (de) 1998-10-08 1999-10-08 Fulvinsäure und deren verwendung in der behandlung von viralen infektionen

Family Applications Before (3)

Application Number Title Priority Date Filing Date
AT99970022T ATE336997T1 (de) 1998-10-08 1999-10-08 Fulvinsäure und dessen verwendung zur behandlung von diversen krankheitszuständen
AT06012245T ATE410160T1 (de) 1998-10-08 1999-10-08 Fulvinsäure und deren verwendung in der behandlung von entzündungen
AT06012244T ATE410159T1 (de) 1998-10-08 1999-10-08 Fulvinsäure und deren verwendung in der behandlung von candida infektionen

Country Status (7)

Country Link
US (1) US6569900B1 (de)
EP (4) EP1700599B1 (de)
JP (1) JP4700808B2 (de)
AT (4) ATE336997T1 (de)
AU (1) AU766198B2 (de)
DE (4) DE69939722D1 (de)
WO (1) WO2000019999A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2570565C (en) * 2004-06-23 2012-10-23 Bioz Agri Products Inc. Method for extracting fulvic acid molecules
ZA200705844B (en) * 2004-12-15 2008-09-25 Van Der Westhuzen Corne Floris Detoxifying and immunity-booster composition
JP2006232785A (ja) * 2005-02-28 2006-09-07 Univ Of Tsukuba フルボ酸を用いるｉ型アレルギー抑制剤及びｉ型アレルギーの発症抑制方法。
US20080160111A1 (en) * 2005-02-28 2008-07-03 Hiroko Isoda Type I Allergy Inhibitor and Methods of Inhibiting the Onset of Type I Allergy Using Fulvic Acid
US20070212434A1 (en) * 2006-03-07 2007-09-13 Day Kenneth S Compositions and methods for human use containing fulvic acid
US8114910B2 (en) 2006-05-02 2012-02-14 Pfeinsmith S.A. (Pty) Ltd. Acidic composition
US8445452B2 (en) 2008-06-05 2013-05-21 Pfeinsmith Ltd. Fulvic acid and antibiotic combination
DE102008058552A1 (de) 2008-11-21 2010-05-27 Mankau, Dieter, Prof. Dr. Federrahmen und Federkörper zur Abstützung z. B. einer Matratze
GB0900786D0 (en) * 2009-01-19 2009-03-04 Natracine Uk Ltd Therapeutic compositions
GB0914966D0 (en) 2009-08-27 2009-09-30 Natracine Uk Ltd Fulvic acid compositions and their use
WO2013023062A1 (en) * 2011-08-09 2013-02-14 Wilford Lynn C Antimicrobial agents and methods for use thereof in the abatement of food borne pathogenic organisms
IN2014DN07194A (de) * 2012-03-07 2015-04-24 Natracine Uk Ltd
CN105246879A (zh) 2013-05-28 2016-01-13 英派尔科技开发有限公司 腐植酸衍生物以及制备的方法和用途
US9932319B2 (en) 2013-05-28 2018-04-03 Empire Technology Development Llc Antioxidant humic acid derivatives and methods of preparation and use
WO2014209369A1 (en) 2013-06-28 2014-12-31 Empire Technology Development Llc Edible plasticizers for food and food packaging films
WO2017102565A1 (en) * 2015-12-15 2017-06-22 Rita Dobmeyer Pharmaceutical composition comprising a fulvic acid and at least one boron-containing compound
US9820953B2 (en) * 2016-02-26 2017-11-21 Omni Bioceutical Innovations, Inc. Compositions of bioactive fulvate fractions and uses thereof
JP6120342B1 (ja) * 2016-03-08 2017-04-26 株式会社スタイルアンドバリュージャパン 美容組成物
US20220160649A1 (en) * 2019-03-20 2022-05-26 Rita DOBMEYER Pharmaceutical composition
EP3799854A1 (de) 2019-10-01 2021-04-07 Stefan Johannes Fellner Extrakt von organischen humifizierten materialien
KR102258006B1 (ko) * 2020-12-22 2021-05-28 허교 풀빅산을 유효성분으로 포함하는 항바이러스 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB244215A (en) 1924-10-09 1925-12-17 Richard William Bailey Improvements in or relating to gas or oil power plant
DE2850685A1 (de) * 1978-11-22 1980-06-04 Kneer Franz X Verfahren zur herstellung eines kolloiden schlammbades und schlammartiger pasten fuer die heilbehandlung
US5204368A (en) * 1990-05-25 1993-04-20 National Energy Council Bacteriostatic and bacteriocidal method using fulvic acid derivatives
JPH0466508A (ja) * 1990-07-03 1992-03-02 Suntory Ltd 抗菌剤
JPH0687752A (ja) * 1992-09-04 1994-03-29 Kyowa Kagaku Kogyo Kk 抗菌水及びこの抗菌水の製造方法
CN1097990A (zh) * 1994-01-29 1995-02-01 康宏盛 一种治疗股癣的药物
JPH1017483A (ja) * 1996-06-26 1998-01-20 Keinzu Corp:Kk 皮膚疾患予防及び治療剤
TR199802702T2 (xx) * 1996-06-27 1999-05-21 Organoflo (Proprietary) Limited Bir s�v� verim artt�rma maddesinin yap�lmas� i�in bir y�ntem.
JPH119674A (ja) * 1997-06-25 1999-01-19 M S K Planning:Kk フミン酸を有効成分とする液体消臭剤と、その製造方法及びフミン酸を有効成分とした飲料用消臭剤と、その製造方法
CN1103339C (zh) * 1998-08-25 2003-03-19 祝亚勤 药用级泥炭黄腐植酸钠的制备方法

Also Published As

Publication number Publication date
JP2002526407A (ja) 2002-08-20
EP1698333B1 (de) 2008-10-08
EP1126837B1 (de) 2006-08-23
EP1700600B1 (de) 2008-10-08
AU766198B2 (en) 2003-10-09
DE69932939T2 (de) 2006-12-07
EP1126837A1 (de) 2001-08-29
EP1700600A1 (de) 2006-09-13
JP4700808B2 (ja) 2011-06-15
DE69939720D1 (de) 2008-11-20
DE69939721D1 (de) 2008-11-20
EP1700599B1 (de) 2008-10-08
EP1700599A1 (de) 2006-09-13
WO2000019999A1 (en) 2000-04-13
AU5992399A (en) 2000-04-26
EP1698333A1 (de) 2006-09-06
ATE410160T1 (de) 2008-10-15
US6569900B1 (en) 2003-05-27
DE69939722D1 (de) 2008-11-20
ATE410159T1 (de) 2008-10-15
DE69932939D1 (de) 2006-10-05
ATE336997T1 (de) 2006-09-15

Similar Documents

Publication Publication Date Title
DE69939722D1 (de) Fulvinsäure und deren Verwendung in der Behandlung von Entzündungen
ATE119520T1 (de) Derivate von hydroxaminsäure und von n- hydroxyharnstoff sowie ihre verwendung.
ATE160561T1 (de) L-carnitin-salz, dieses enthaltende kosmetische und pharmazeutische zusammensetzungen zur behandlung von dermatosen
DE69103773D1 (de) Derivate von hydroxaminsäure die lipoxygenase hemmen.
ATE185803T1 (de) N-hydroxy-harnstoff-derivate als entzündunghemmende mittel
ATE271896T1 (de) Salbe enthaltend mometason-furoat und salicylsäure zur topischen behandlung von psoriasis
BR9608721A (pt) Composição farmacêutica, e, processo para tratar inflamação
ATE193537T1 (de) Phosphorylierte derivate von verbindungen mit antiinflammatorischen oder analgetischer wirkung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties